{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T20:15:15Z","timestamp":1768853715811,"version":"3.49.0"},"reference-count":11,"publisher":"Informa UK Limited","issue":"1","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Journal of Immunotoxicology"],"published-print":{"date-parts":[[2019,1,1]]},"DOI":"10.1080\/1547691x.2019.1610117","type":"journal-article","created":{"date-parts":[[2019,6,8]],"date-time":"2019-06-08T09:54:13Z","timestamp":1559987653000},"page":"133-139","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":9,"title":["Topical minocycline foam 4%: Results of four phase 1 studies evaluating the potential for phototoxicity, photoallergy, sensitization, and cumulative irritation"],"prefix":"10.1080","volume":"16","author":[{"given":"Jonathan","family":"Dosik","sequence":"first","affiliation":[{"name":"TKL Research, Inc., Fair Lawn, NJ, USA;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Herman","family":"Ellman","sequence":"additional","affiliation":[{"name":"Formerly Foamix Pharmaceuticals, Inc. (Ret.), Bridgewater, NJ, USA;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iain","family":"Stuart","sequence":"additional","affiliation":[{"name":"Foamix Pharmaceuticals, Inc., Bridgewater, NJ, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2019,6,8]]},"reference":[{"key":"CIT0001","first-page":"CD002086","volume":"8","author":"Garner S","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"CIT0002","doi-asserted-by":"crossref","unstructured":"Gold L, Dhawan S, Weiss J, Draelos Z, Ellman H. 2018. FMX101 4% minocycline foam for the treatment of acne vulgaris: Safety and patient satisfaction from the open-label extension of two Phase 3 studies. Presented at: Winter Clinical Dermatology Conference; January 12\u201317; Maui, HI.","DOI":"10.25251\/skin.3.supp.1"},{"key":"CIT0003","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.08.020"},{"key":"CIT0004","first-page":"327","volume":"70","author":"Housman T","year":"2002","journal-title":"Cutis"},{"key":"CIT0005","first-page":"1022","volume":"16","author":"Jones T","year":"2017","journal-title":"J Drugs Dermatol"},{"key":"CIT0006","doi-asserted-by":"publisher","DOI":"10.2165\/11319280-000000000-00000"},{"key":"CIT0007","doi-asserted-by":"crossref","unstructured":"Raoof J, Hooper D, Moore A, Zaiac M, Sullivan T, Kircik L, Lain E, Jankicevik J, Stuart I. 2018. FMX101 4% topical minocycline foam for the treatment of moderate-to-severe acne vulgaris: Efficacy and safety from a Phase 3 randomized, double-blind, vehicle-controlled study. Presented at: Fall Clinical Dermatology Conference; October 18\u201321; Las Vegas, NV.","DOI":"10.25251\/skin.2.supp.56"},{"key":"CIT0008","unstructured":"Solodyn\u00ae [package insert]. 2016. Bridgewater (NJ): Valeant Pharmaceuticals North America LLC; [accessed 2019 Apr 11]. http:\/\/www.solodyn.com."},{"key":"CIT0009","doi-asserted-by":"publisher","DOI":"10.1517\/17425247.3.6.799"},{"key":"CIT0010","unstructured":"U.S. Food and Drug Administration (UD FDA). 2018. Guidance, compliance, and regulatory information. Updated 2018 Dec 11. https:\/\/www.fda.gov\/Drugs\/GuidanceCompliance Regulatory Information\/default.htm. Accessed 2019 Apr 11."},{"key":"CIT0011","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2015.12.037"}],"container-title":["Journal of Immunotoxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/tandfonline.com\/doi\/pdf\/10.1080\/1547691X.2019.1610117","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/1547691X.2019.1610117","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,5]],"date-time":"2020-09-05T03:09:48Z","timestamp":1599275388000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/1547691X.2019.1610117"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,1]]},"references-count":11,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,1,1]]}},"alternative-id":["10.1080\/1547691X.2019.1610117"],"URL":"https:\/\/doi.org\/10.1080\/1547691x.2019.1610117","relation":{},"ISSN":["1547-691X","1547-6901"],"issn-type":[{"value":"1547-691X","type":"print"},{"value":"1547-6901","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,1]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iimt20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iimt20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2019-03-15","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-04-12","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-04-17","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-06-08","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}